|
|
|
| Advances in metabolomics - based studies of differential metabolites in cancer cachexia |
| 1,2Xu Jing,1,2Chen Meiyu,1,2Zhang Dameng,1,2Du Peilong,1Zhu Xinting,1Han Leng,1Guo Cheng,1,2Yang Quanjun |
| 1Department of Pharmacy Shanghai Sixth People's Hospital Affiliated Shanghai Jiaotong University School of Medicine Shanghai
200233 China
2
Shanghai University of Medicine & Health Sciences Shanghai 201318 China |
|
|
|
|
Abstract Cancer cachexia is a complex multifactorial systemic syndrome that characterized by metabolic disorders mediating
muscle atrophy and weight loss. Cancer cachexia is not only a contraindication to the comprehensive cancer treatment such as
chemotherapy but also a deteriorating state with decreasing quality of life and short survival. Cancer cachexia occurs in 50%-80% of
cancer patients with an incidence of over 85% in patients with pancreatic lung and gastric cancer. In addition 20% of cancer
patients die as a result of the enormous wasting associated with cachexia. Metabolomics technology reveals the metabolic pathogenesis of
diseases through the study of changes in the composition and concentration of metabolites and has been widely used in recent years for
the characterisation and biomarker studies of tumours and metabolic diseases to elucidate the metabolic interactions of multiple
tissues. In the present study we summarised the metabolic changes and pathways of cancer cachexia to elucidate the fundamental
metabolic reprogramming of cancer cachexia. We reviewed the current status of biomarker research and the mechanism of cancer
cachexia resulting from different types of cancer. By comparing the metabolic profiles of cancer cachexia from clinical samples and
animal models we analysed the metabolic interactions of different cancer cachexias. The present study not only provides new ideas for
the diagnosis and prevention of cancer cachexia but also new strategies for drug target
research and clinical intervention research.
|
|
|
|
|
|
|
|
|
